Skip to content

A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-500660-35-00
Acronym
2390-CL-0001
Enrollment
28
Registered
2023-03-21
Start date
2020-02-17
Completion date
Unknown
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy to House Dust Mites

Interventions

None listed

Sponsors

Astellas Pharma Global Development Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026